| Initial eradication cohort |  | PA stratified cohort | ||||
---|---|---|---|---|---|---|---|
N (%) or mean (std) | Azithromycin (N = 101) | Placebo (N = 97) |  | Single TIS + AZ (N = 42) | Single TIS + Placebo (N = 43) | Three TIS series + AZ (N = 13) | Three TIS series + Placebo (N = 10) |
Age in years | 6.7 (5) | 6.9 (5) | Â | 6.1 (5) | 7.2 (5) | 8.8 (4) | 7.5 (6) |
Female | 52 (51%) | 44 (45%) | Â | 21 (50%) | 21 (49%) | 6 (46%) | 3 (30%) |
Caucasian | 92 (91%) | 83 (86%) | Â | 39 (93%) | 38 (88%) | 13 (100%) | 9 (90%) |
Genotype (F508del copy #) | |||||||
 2 | 58 (57%) | 49 (51%) |  | 28 (67%) | 22 (51%) | 7 (54%) | 5 (50%) |
 1 | 28 (28%) | 41 (42%) |  | 8 (19%) | 19 (44%) | 5 (38%) | 5 (50%) |
 0/not done | 15 (15%) | 7 (7%) |  | 6 (14%) | 2 (5%) | 1 (8%) | 0 |
FEV1% pred | N = 63 |  N = 56 |  |  N = 24 |  N = 27 |  N = 11 |  N = 6 |
 < 75% | 5 (8%) | 7 (12%) |  | 2 (8%) | 2 (8%) | 0 | 1 (17%) |
 75-100% | 31 (49%) | 30 (54%) |  | 12 (50%) | 16 (59%) | 6 (55%) | 4 (66%) |
 >= 100% | 27 (43%) | 19 (34%) |  | 10 (42%) | 9 (33%) | 5 (45%) | 1 (17%) |
First lifetime PA+ | 60 (59%) | 58 (60%) | Â | 26 (62%) | 22 (51%) | 7 (54%) | 7 (70%) |
CFTR modulator use at baseline (Ivacaftor or Ivacaftor/lumacaftor) | 4 (4%) | 6 (6%) | Â | 1 (2%) | 3 (7%) | 1 (8%) | 1 (10%) |
Culture result at baseline* | |||||||
 P. aeruginosa | 51 (51%) | 41 (44%) |  | 15 (36%) | 16 (38%) | 11 (85%) | 6 (60%) |
 S. aureus | 51 (51%) | 57 (61%) |  | 22 (52%) | 25 (60%) | 6 (46%) | 5 (50%) |
 H. influenzae | 8 (8%) | 11 (12%) |  | 4 (10%) | 6 (14%) | 2 (15%) | 0 |
 S. maltophilia | 2 (2%) | 3 (3%) |  | 1 (2%) | 2 (5%) | 1 (8%) | 1 (10%) |